< Arab Finance - News - Rameda’s consolidated profits balloon 101.1% YoY in H1
Count Down to relaunch



Rameda’s consolidated profits balloon 101.1% YoY in H1

Rameda’s consolidated profits balloon 101.1% YoY in H1

ArabFinance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) (RMDA) registered a 101.09% year-on-year (YoY) surge in consolidated profit attributable to the parent company during the first half (H1) of 2022, recording EGP 124.204 million, according to financial statements filed to the Egyptian Exchange (EGX) on Monday.

Consolidated revenue surged to EGP 711.5 million in H1 2022 from EGP 537.772 million in H1 2021.

The company’s standalone net profit after tax reached EGP 125.239 million in the six-month period ended June 30th, up from EGP 62.097 million the year before.

Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals. It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.

 

 

Recommended Stocks

13 Jun 2022
Delta Sugar SUGR
Close
14.09
Change
-00.7
Hold

All rights reserved to Arab Finance 2020 ©

Back to top